Emicizumab for kids with hemophilia A
Part of Blood & lymphatic, Bones, joints & muscles, Genetic & congenital clinical trials.
This trial tests emicizumab, a medicine given under the skin, to see how it works in children with hemophilia A. It aims to help control bleeding, no matter if they have inhibitors or not.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be under 18 years old.
- You must have been diagnosed with hemophilia A.
- Your clotting factor level must be 1% or less.
- You can have inhibitors (antibodies that block treatment) or not.
- You and your doctor agree you are ready to start emicizumab injections.
- You are willing to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
This trial compares two low-dose prophylactic treatments for severe hemophilia A. Patients receive either low-dose emicizumab or low-dose factor VIII to see which works better for preventing bleeding episodes.
This study looks at whether aPCC (a clotting medicine) is safe to use for bleeding safety in people with hemophilia A who are already taking emicizumab. It mainly checks side effects and safety after switching to or using aPCC when needed.
This study compares two preventive treatments for severe hemophilia A—emicizumab versus factor VIII—to see how they affect joint and bone health. It may help you and others understand which option better protects joints and bones over the next several years.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.